文献速递睡眠呼吸障碍

持续气道正压通气改善阻塞性睡眠呼吸暂停合并高血压患者的血压和血清心血管生物标志物

Continuous positive airway pressure improves blood pressure and serum cardiovascular biomarkers in obstructive sleep apnoea and hypertension.
PubMed 文献 · Eur Respir J · 2021-11-04

本研究为平行组随机对照试验,纳入需至少三种降压药控制血压的中重度阻塞性睡眠呼吸暂停合并高血压患者92例,随机接受8周CPAP治疗或无CPAP对照。结果显示CPAP组24小时及日间血压显著降低,且仅非杓型血压者获益,血清肌钙蛋白I和脑钠肽显著降低。

要点

  • CPAP治疗8周可显著降低中重度OSA合并难控高血压患者的24小时和日间血压。
  • 血压改善仅见于非杓型血压患者,杓型血压者未获益。
  • CPAP还降低血清肌钙蛋白I和脑钠肽,提示减轻亚临床心肌损伤和牵张。

核心结论

  • 在合并多种心血管危险因素(包括难控高血压)的OSA患者中,短期CPAP治疗改善动态血压并减轻亚临床心肌损伤和牵张。

研究设计与样本

  • 平行组随机对照试验,纳入需至少三种降压药的中重度OSA合并高血压患者,随机1:1接受CPAP治疗或无CPAP对照8周,比较动态血压和血清生物标志物变化。
  • 共92例受试者,75%男性,平均±标准差年龄51±8岁,呼吸暂停低通气指数40±8 events·h-1,平均服用3.4(范围3-6)种降压药。

主要发现

  • CPAP组较对照组24小时收缩压降低-4.4(95%CI -8.7至-0.1)mmHg(p=0.046),24小时舒张压降低-2.9(95%CI -5.5至-0.2)mmHg(p=0.032)。
  • CPAP组日间收缩压降低-5.4(95%CI -9.7至-1.0)mmHg(p=0.016),日间舒张压降低-3.4(95%CI -6.1至-0.8)mmHg(p=0.012)。
  • CPAP组较对照组血清肌钙蛋白I平均差-1.74(95%CI -2.97至-0.50)pg·mL-1(p=0.006),脑钠肽平均差-9.1(95%CI -17.6至-0.6)pg·mL-1(p=0.036)。
  • CPAP治疗的血压降低仅见于非杓型血压者,杓型血压者未见显著降低。

临床怎么用

  • 对中重度OSA合并难控高血压患者,可考虑短期CPAP治疗以改善动态血压和亚临床心肌损伤。
  • 非杓型血压的OSA合并高血压患者可能是CPAP降压治疗更可能获益的人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of treatment for obstructive sleep apnoea (OSA) on reduction of cardiovascular risk is unclear. This study aimed to examine the effect of continuous positive airway pressure (CPAP) on ambulatory blood pressure (BP) and subclinical myocardial injury in subjects with OSA and hypertension. METHODS: This was a parallel-group randomised controlled trial. Subjects with hypertension requiring at least three antihypertensive medications and moderate-to-severe OSA were enrolled. Eligible subjects were randomised (1:1) to receive either CPAP treatment or control (no CPAP) for 8 weeks. Changes in ambulatory BP and serum biomarkers were compared. Stratified analysis according to circadian BP pattern was performed. RESULTS: 92 subjects (75% male; mean±sd age 51±8 years and apnoea-hypopnoea index 40±8 events·h-1, taking an average of 3.4 (range 3-6) antihypertensive drugs) were randomised. The group on CPAP treatment, compared with the control group, demonstrated a significant reduction in 24-h systolic BP (-4.4 (95% CI -8.7- -0.1) mmHg; p=0.046), 24-h diastolic BP (-2.9 (95% CI -5.5- -0.2) mmHg; p=0.032), daytime systolic BP (-5.4 (95% CI -9.7- -1.0) mmHg; p=0.016) and daytime diastolic BP (-3.4 (95% CI -6.1- -0.8) mmHg; p=0.012). CPAP treatment was associated with significant BP lowering only in nondippers, but not in dippers. Serum troponin I (mean difference -1.74 (95% CI -2.97- -0.50) pg·mL-1; p=0.006) and brain natriuretic peptide (-9.1 (95% CI -17.6- -0.6) pg·mL-1; p=0.036) were significantly reduced in CPAP compared with the control group. CONCLUSIONS: In a cohort with OSA and multiple cardiovascular risk factors including difficult-to-control hypertension, short-term CPAP treatment improved ambulatory BP, and alleviated subclinical myocardial injury and strain.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Lui MM, Tse HF, Lam DC, et al. Continuous positive airway pressure improves blood pressure and serum cardiovascular biomarkers in obstructive sleep apnoea and hypertension. Eur Respir J. 2021. PMID: 33795324. doi:10.1183/13993003.03687-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。